Volatility is returning to Wall Street, signaling a potential fracture in the bull market sentiment that defined the previous year. Recent trading sessions have seen Nasdaq futures face noticeable downward pressure, a stark contrast to the smooth sailing investors grew accustomed to in 2025. The p.... |
Good MorningStocks ended the day driven by big tech and bank headlines. NVIDIA’s CES showcase and RTX 60-Series debut helped the chip giant briefly push market value above $4.76 trillion before cooling back toward $4.5–$4.6 trillion, keeping AI enthusiasm at the market’s center. JPMorgan reported a 9% adjusted profit rise in Q4—$13.03 billion, or $4.63 a share—though results were trimmed by a one-time 60-cent charge tied to its Apple Card acquisition and $2.2 billion added to loan-loss reserves. December inflation was mostly unchanged while core prices cooled slightly, a development markets watch closely for Fed policy signals.
Policy risk and regulation crept into market thinking. Nine central bankers voiced full solidarity with Fed Chair Powell amid President Trump’s escalating confrontations with the Fed, and Wall Street executives warned that attacks on regulators and the credit card industry could unsettle markets. Microsoft’s Brad Smith pressed lawmakers for Big Tech to shoulder the costs of sprawling AI data centers, signaling potential regulatory and cost pressures for cloud and chip providers. Featured: 120 days remain before new defense mineral rules take effect (Ad) 
| Markets | |
Volatility is returning to Wall Street, signaling a potential fracture in the bull market sentiment that defined the previous year. Recent trading sessions have seen Nasdaq futures face noticeable downward pressure, a stark contrast to the smooth sailing investors grew accustomed to in 2025. The p... Read the Full Story |
| From Our Partners | | Barrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldrush, and Cortez Hills, deposits that could hold up to 60 million ounces of gold.
One overlooked explorer controls 142 claims bordering Fourmile and sitting less than a mile from Goldrush. New geological modeling aims to reveal what's beneath this largely untested ground, while a planned 5% royalty spin-off could give shareholders a separate stake in the project. | | Read the full report before the next catalyst hits |
| Healthcare | |
In the last few months of 2025, shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) went on an undeniable hot streak. From the beginning of August 2025 to the end of the year, the stock rose 41%. Optimism surrounding Lilly’s current and developmental weight loss and diabetes t... Read the Full Story |
| Finance | |
A convergence of factors has JPMorgan Chase & Company (NYSE: JPM) stock poised to rally in 2026. The stock surged in 2025 and could advance as much as 20% by year’s end. Below, we'll examine what's driving the JPM market and why the financial stock could see the $400 level this year.
Ja... Read the Full Story |
| From Our Partners | | A 60-minute morning window is catching traders' attention for one reason: it doesn't depend on market direction.
Place a quick trade before 10 am, then step away. Sixty minutes later, the setup has already done its work.
The strategy targets a 50 percent return potential on a $1,000 stake, though results vary and some trades won't work out. | | Discover how to apply this 60 minute trading window today |
| Consumer Discretionary | |
Shares of tech giant Amazon.com Inc (NASDAQ: AMZN) surged more than 10% last week, starting what looks like what could be a decisive run toward November's all-time high. The move hasn't come out of the blue. For months now, the stock has been carving out a steady series of higher lows, quietly b... Read the Full Story |
| Technology | |
In the middle of January 2026, the two largest forces in mobile computing effectively called a truce in the war for artificial intelligence (AI) dominance. After months of speculation and market volatility, Apple Inc. (NASDAQ: AAPL) and Alphabet Inc. (NASDAQ: GOOG) formalized a strategic partnersh... Read the Full Story |
| From Our Partners | | A 20-minute read could change how you approach your next options trade. Chris Pulver is giving away his guide, Right About The Market, Wrong About The Money, free of charge.
Built from two decades of trading experience, the guide tackles a common problem: losing a trade even when your market call was correct.
No cost, no catch, just a packed resource for options traders who want a sharper edge. | | Click here to get your free copy of the guide |
| Finance | |
The market reaction in the finance and fintech sectors on Jan. 12, 2026, was not a panic sell-off. It was a precise, calculated sorting event. Following the Trump administration's announcement of a proposed 10% cap on credit card interest rates, the financial sector fractured. While the headlines ... Read the Full Story |
| Technology | |
NVIDIA (NASDAQ: NVDA) has achieved a level of dominance in the stock market that defies historical comparison. The chip giant's market capitalization briefly peaked above $4.76 trillion following its dominant presentation at CES 2026, which featured the debut of its new consumer-focused RTX 60-Ser... Read the Full Story |
| Consumer Discretionary | |
After gaining just 6% last year, consumer discretionary stocks entered 2026 looking for some relief from the fallout from tariffs, margin compression, and a weakening labor market.
But for automotive stocks, the situation was a little different. According to Autoweek, U.S. auto sales were strong... Read the Full Story |
| Markets | |
In the face of inflation, changing interest rates, and broader market instability, income-generating exchange-traded funds (ETFs) may be a strong defensive choice for investors in 2026. These funds offer the benefit of steady distributions by focusing on dividend-paying stocks, on bonds, or on oth... Read the Full Story |
| Technology | |
AI is a fast-growing market whose outlook has yet to be fully reflected in its stock prices. While it's hard to say for certain which AI infrastructure, model builder, or application will stand the test of time, it is certain that AI and the cloud are here to stay.
Many organizations use multiple... Read the Full Story |
| Wednesday's Early Bird Stock Of The Day Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. | Should I Buy Pfizer Stock? PFE Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Pfizer was last updated on Wednesday, August 26, 2026 at 6:16 PM.
Pfizer Bull Case -
Pfizer Inc. recently reported earnings per share (EPS) of $0.77, exceeding analyst expectations, which indicates strong financial performance and potential for future growth.
-
The company has a solid revenue stream, with quarterly revenue reaching $15.03 billion, surpassing estimates, suggesting robust demand for its products.
-
Pfizer Inc. has set a favorable guidance for FY 2026, projecting EPS between 2.800 and 3.000, which may attract investors looking for growth opportunities.
-
The current stock price is around $28.28, which is considered reasonable given the company's performance and market position, making it an attractive entry point for new investors.
-
With a dividend yield of 6.1%, Pfizer Inc. offers a reliable income stream for investors, which is particularly appealing in uncertain market conditions.
Pfizer Bear Case -
The company's payout ratio is notably high at 226.32%, which may raise concerns about sustainability of dividend payments in the long term.
-
Recent analyst downgrades and reduced price targets from firms like JPMorgan and Bank of America indicate a cautious outlook on the stock's performance.
-
Pfizer Inc. has experienced a slight decline in EPS compared to the same quarter last year, which could signal potential challenges in maintaining growth.
-
With a consensus rating of "Hold" from analysts, there may be limited upside potential in the stock, suggesting that it may not be the best investment for aggressive growth seekers.
-
The biopharmaceutical sector is facing significant challenges, including patent cliffs and regulatory pressures, which could impact Pfizer Inc.'s future profitability.
| | View Today's Stock Pick |
|
| |
|
|
